ASX:MSBBiotechs
A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans
Mesoblast (ASX:MSB) has drawn fresh attention after appointing Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, a move that coincides with its upcoming Bell Potter Healthcare Horizons Summit presentation.
See our latest analysis for Mesoblast.
The recent appointment and upcoming summit appearance come after a tougher stretch for the share price, with a 30 day share price return of 14.4% and a 90 day share price return of 22.74%. However, the 3 year total...